We are excited to announce that our co-founders Prof. Dr. Karen Vanhoorelbeke and Dr. Shannen Deconinck will be representing Hemastatx at the ISTH 2025 Congress.
Organized by the International Society on Thrombosis and Haemostasis, the ISTH Congress is the premier annual event for experts in thrombosis and hemostasis. This year's congress takes place in Washington, D.C., from June 21-25, 2025, and will feature groundbreaking research and networking opportunities.
Dr. Deconinck, Preclinical R&D Lead at Hemastatx, will be delivering an oral communication titled "Therapeutic Efficacy of a Novel Anti-ADAMTS13 Antibody to Treat Acquired von Willebrand Syndrome”. The study was led by KU Leuven Kulak’s Laboratory for Thrombosis Research. Results highlight the potential of Hemastatx’s lead program, HMX-001, to prevent the loss of high-molecular-weight von Willebrand factor multimers and reduce bleeding complications in left ventricular assist device patients.
Join us at the congress to learn more about this promising research and its impact on the treatment of acquired von Willebrand syndrome.
Great to see the newest edition of VOKA's "Entrepreneurs" magazine featuring KU Leuven Kulak and Hemastatx.
The article (in Dutch) highlights how academic innovation at the Laboratory for Thrombosis Research was at the basis for Hemastatx's foundation earlier this year. Our lead program, HMX-001, aims to help patients with severe bleeding episodes worldwide.
Published on
October 1, 2025
Share this
News
Other news & updates
News
June 19, 2025
